Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURE-ALS2: Inosine in ALS
NCT03168711Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Inosine with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events at 24 weeks and Tolerability to Complete the Entire 20 Week Study on Study Drug. Started Oct 2017; status: completed.
02
Drugs
inosine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03168711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168711.